Impax Laboratories appoints Frederick Wilkinson as President and CEO
US generic drugmaker Impax Laboratories (NASDAQ: IPXL) has announced the appointment of Frederick Wilkinson as President and Chief Executive Officer effective April 29, 2014.
Mr Wilkinson (pictured), who previously served as President, Actavis Global Research and Development at Actavis plc succeeds Larry Hsu who is retiring.
“A long-time industry leader, Fred's extensive experience in managing generic, brand, R&D, and regulatory and compliance activities, together with his track record in driving change, delivering growth, advancing pipeline products and driving innovation, make him the perfect candidate for this role,” said Robert Burr, Chairman of Impax Laboratories. “I have every confidence that Fred's vision and passion will translate into remarkable success for Impax. The Board would like to thank Dr Hsu for his incredible dedication and commitment over the last 18 years and for positioning the Company for its next phase of growth.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze